Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Metanx Effects on Nerve Fiber Density in Neuropathic Diabetics (SLHN2011-18)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01503892
Recruitment Status : Unknown
Verified July 2012 by Edwin S. Hart III, St. Luke's Hospital and Health Network, Pennsylvania.
Recruitment status was:  Recruiting
First Posted : January 4, 2012
Last Update Posted : July 17, 2012
Sponsor:
Collaborators:
Goldfarb Foundation
Pamlab, L.L.C.
Information provided by (Responsible Party):
Edwin S. Hart III, St. Luke's Hospital and Health Network, Pennsylvania

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study focuses on the use of Metanx® as the sole treatment for improving and reversing nerve damage in type 2 diabetic patients with peripheral neuropathy. There will be two equal study groups enrolled in this randomized double blinded study. The minimum sample size of enrollment is 24 (12 per group), which is required for 90% power at alpha = .05. The maximum number of participants will be set at 100 (50 per group). Patients who are pre-diabetic or patients who have been diagnosed with diabetes type II for less than five years are included in this study. The control group will receive placebo pill twice daily versus the treatment group which will receive one Metanx® tablet twice daily. Each group will have intraepidermal nerve fiber densities obtained by skin biopsies taken at the beginning of the study before any treatment has begun as well as a final intraepidermal nerve skin biopsy at the end of twelve months to re-biopsy. In addition each group will answer three sets of questionnaires relating to their peripheral neuropathy at initial, three months, twelve month visitations. If Metanx® is able to reverse nerve damage and improve symptoms then the final nerve biopsies will show an increase in intraepidermal nerve fiber density and an improvement in the subjective score versus the placebo group.

Condition or disease Intervention/treatment Phase
Diabetes Peripheral Neuropathy Dietary Supplement: Metanx Drug: Placebo Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Metanx Effects on Nerve Fiber Density in Neuropathic Diabetics
Study Start Date : December 2011
Estimated Primary Completion Date : October 2013

Resource links provided by the National Library of Medicine

Drug Information available for: Mecobalamin

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Placebo Comparator: Placebo
The control group will receive placebo pill twice daily for twelve months.
 Drug: Placebo
Placebo- one tablet twice daily for twelve months.
Active Comparator: Metanx
Metanx group will receive one pill twice daily for twelve months.
 Dietary Supplement: Metanx
Metanx- one tablet twice daily for twelve months


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Increased intraepidermal nerve fiber density [ Time Frame: 1 year ]
    If Metanx® is able to reverse nerve damage and improve symptoms then the final nerve biopsies will show an increase in intraepidermal nerve fiber density


Secondary Outcome Measures :
  1. Subjective improvement [ Time Frame: 1 year ]
    Improvement in the subjective score versus the placebo group.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Type 2 Diabetics
  • Pre-diabetics
  • Symptoms of peripheral neuropathy

Exclusion Criteria:

  • Pregnancy
  • Under age 18
  • HIV (+)
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01503892


Contacts
Layout table for location contacts
Contact: Edwin S. Hart III, DPM 610-868-4300 ehart@footmed.com

Locations
Layout table for location information
United States, Pennsylvania
St. Luke's Hospital and Health Network Recruiting
Bethlehem, Pennsylvania, United States, 18015
Contact: Edwin S. Hart III, DPM    610-868-4300    ehart@footmed.com   
Sponsors and Collaborators
St. Luke's Hospital and Health Network, Pennsylvania
Goldfarb Foundation
Pamlab, L.L.C.
Investigators
Layout table for investigator information
Principal Investigator: Edwin S. Hart III, DPM St. Luke's Hospital and Health Network
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Additional Information:
William L. Goldfarb Educational Foundation for Research and Teaching of the Lower Extremity  This link exits the ClinicalTrials.gov site PamLab  This link exits the ClinicalTrials.gov site St. Luke's Hospital and Health Network  This link exits the ClinicalTrials.gov site

Layout table for additonal information
Responsible Party: Edwin S. Hart III, Principal Investigator, St. Luke's Hospital and Health Network, Pennsylvania
ClinicalTrials.gov Identifier: NCT01503892     History of Changes
Other Study ID Numbers: StLukeHHN
First Posted: January 4, 2012    Key Record Dates
Last Update Posted: July 17, 2012
Last Verified: July 2012

Keywords provided by Edwin S. Hart III, St. Luke's Hospital and Health Network, Pennsylvania:
Small Fiber Neuropathy
Metanx Effect on Small Fiber Neuropathy
Metanx Effect on Diabetic Peripheral Neuropathy

Additional relevant MeSH terms:
Layout table for MeSH terms
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Vitamin B 12
Vitamin B Complex
 Vitamins
Micronutrients
Nutrients
Growth Substances
Physiological Effects of Drugs